fda drug safety communication semaglutide naion 2025 linked to increased risk of vision loss in diabetes patients The Double-Edged Sword: Ozempic For

By mimicking this hormone, GLP-1 receptor agonists can treat type 2 diabetes and/or obesity by promoting insulin secretion, slowing digestion, and helping you feel full

Evidence from Observational Studies A matched cohort study published in JAMA Ophthalmology reported a higher incidence of NAION in patients prescribed semaglutide compared with those receiving non-GLP-1 agents

New York: Oxford University Press

Ipamorelin works quickly, supports short bursts of growth hormone, and is very well tolerated

Hair loss associated with GLP-1 medications appears to be related to rapid weight loss rather than the medications themselves